Rostami Amirabbas, Abbasi Yusef, Jamalnia Sheida, Asadian Asma, Enani Hossein, Jafarinia Morteza
Department of Internal Medicine, Faculty of General Medicine, Yerevan State Medical University after Mkhitar Heratsi, Yerevan, Armenia.
Department of Anatomy, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Galen Med J. 2022 Dec 17;11:e2529. doi: 10.31661/gmj.v11i.2529. eCollection 2022.
Multiple sclerosis (MS) is a high-prevalence autoimmune and neurodegenerative disease that affects young adults. An ideal treatment for MS should have two characteristics. First, its immunosuppression and immunomodulation effects reduce the abnormal immune response, and second, it improves repair by enhancing intrinsic repair processes or even cell replacement. Most available therapies have the first characteristic. Recent studies have proposed mesenchymal stem cells (MSCs) as a new therapeutic candidate for MS. Different clinical trials and animal models of MS have shown the therapeutic effect of MSCs. In the current study, we reviewed the therapeutic effects of MSCs in the animal model and patients with MS.
多发性硬化症（MS）是一种影响年轻人的高发性自身免疫性和神经退行性疾病。MS的理想治疗方法应具备两个特点。其一，其免疫抑制和免疫调节作用可降低异常免疫反应；其二，它通过增强内在修复过程甚至细胞替代来改善修复。大多数现有疗法具备第一个特点。最近的研究提出间充质干细胞（MSCs）作为MS的一种新的治疗候选方法。不同的MS临床试验和动物模型已显示出MSCs的治疗效果。在本研究中，我们综述了MSCs在MS动物模型和患者中的治疗效果。
